Formulation Development
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for Anti-Infectives
Recce Pharmaceuticals Limited recently announced the Intellectual Property Department of the Hong Kong Special Administrative Region has granted patent family three, Anti-Virus Agent and Method…
LIXTE Biotechnology Announces Preclinical Results of its Collaboration With the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity
LIXTE Biotechnology Holdings, Inc. recently announced Professor René Bernards, Netherlands Cancer Institute (NKI), Amsterdam, presented new data from promising drug combinations of LIXTE’s lead clinical…
Venomtech Announces New Drug Development Collaboration With Charles River
Venomtech is collaborating with Charles River Laboratories, International Inc. to help drug developers explore venom-derived compounds for a wide range of….
WHITE PAPER: Controlled Synthesis of Lipid Nanoparticles Using the Automated Nanoparticle System
Particle Works’ leading microfluidic technology offers a unique automated nanoparticle generation platform for the production of homogeneous, controllable, and reproducible LNPs….
Matinas BioPharma & BioNTech Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
Matinas BioPharma and BioNTech SE recently announced they have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and….
Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
Krystal Biotech, Inc. recently announced it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extension study,…
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
Diffusion Pharmaceuticals Inc. recently announced the final participant has completed dosing in its Altitude Trial. The Altitude Trial is a double-blind, randomized, placebo-controlled crossover study,…
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection
Eton Pharmaceuticals, Inc. recently announced it has received final approval from the US FDA for its cysteine hydrochloride abbreviated new drug application (ANDA), a bioequivalent generic of….
AEON Biopharma Completes Enrollment in Phase 2 Clinical Study
AEON Biopharma, Inc. recently announced the completion of patient enrollment in the Phase 2 clinical study of ABP-450 (prabotulinumtoxinA) for the treatment of cervical dystonia.…
VectorBuilder to Expand With $500-Million Gene Delivery Research & Manufacturing Campus
VectorBuilder Inc. recently announced the construction of a new R&D and manufacturing center in Guangzhou, China. The Gene Delivery Research and Manufacturing Campus will significantly expand…
Context Therapeutics Announces Encouraging Preclinical Data From Two Programs
Context Therapeutics Inc. recently announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s…
Enteris BioPharma Highlighted as Game Changer in Special Feature on Innovative Technologies for Improving Drug Solubility & Bioavailability
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq:…
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data From Phase 1b/2a Trial
VYNE Therapeutics Inc. recently announced positive efficacy results from the Phase 1b segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of…
FREEZE-DRYING MICROSCOPY - Unravelling the Complexities of Freeze-Drying Pharmaceuticals With Advanced Microscopy Techniques
Paul Matejtschuk, PhD, Prof Yvonne Perrie, and Robert Gurney, PhD, say FDM is being used to analyze the most challenging formulations that require sophisticated stabilization methods. By altering and adapting the three main freeze-drying stages to specific formulations, researchers are providing the tools needed for the pharma industry to improve its drug development processes and maintain drug stability when scaling up to production.
Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK & Across Europe
Catalent recently announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under….
Rhythm Pharmaceuticals Optimizes Design of EMANATE & DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity
Rhythm Pharmaceuticals, Inc. recently announced modifications intended to optimize its Phase 3 EMANATE and ongoing Phase 2 DAYBREAK trials to focus on rare patient populations,…
Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp & Body Psoriasis
Arcutis Biotherapeutics, Inc. recently announced the enrollment of the last subject in its ARRECTOR pivotal Phase 3 trial of topical roflumilast foam in adolescents and…
Medidata & Celsion Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
Celsion Corporation and Medidata recently announced they presented their findings on the use of a Synthetic Control Arm (SCA) in a completed Phase Ib dose-escalating study of GEN-1 in the neoadjuvant treatment of….
CELL & GENE THERAPY - State of the Industry – Where is C> Headed?
Bill Vincent believes if the industry wants to keep moving up the steep growth curve, then capacity and raw materials must be readily available. The innovations in therapies, platforms, and processes will all come with time, money, and increasing availability of resources.
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of Drug-Enhanced Cell Therapy for the Treatment of Patients With Solid Tumors
Nurix Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy and….
